Prostate Cancer Patients Articles & Analysis: Older
37 news found
In this piece, we talked to the two presenters of the poster “The Validation of a Homologous Recombination Deficiency Assay into Clinical Practice within the NHS”, Elizabeth Ratsma, Pre-Registration Clinical Scientist – Cancer Genomics and Charlotte Flanagan, PhD, Innovation Lead, from The Royal Marsden NHS Foundation Trust. The poster was recently presented at the ESMO ...
Almost all early-stage prostate cancers are androgen-dependent.4 Up to 50% of patients with prostate cancer develop elevated prostate-specific antigen (PSA) levels in their blood after primary therapy (surgery and/or radiation therapy).5 This disease state is called biochemical recurrence (BCR). ...
ByBayer AG
Nubeqa now approved for metastatic hormone-sensitive prostate cancer as well as non-metastatic castration-resistant prostate cancer Additional indication based on data from the pivotal Phase III ARASENS trial The Chinese National Medical Products Administration (NMPA) has approved the oral androgen receptor inhibitor (ARi) ...
ByBayer AG
Nubeqa is already approved for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease. ...
ByBayer AG
“The number of prostate cancer patients in Japan has increased rapidly in recent years, almost doubling in the past decade. ...
ByBayer AG
“An important part of our mission at Bayer is to transform prostate cancer care and improve patient outcomes at various stages of the disease. ...
ByBayer AG
Darolutamide is being investigated in a broad development program with additional three ongoing or planned large clinical studies, to investigate its potential across prostate cancer patients from the early- to the late-stage of this disease. ...
ByBayer AG
Nubeqa™ (darolutamide), which has the potential to become the standard of care for prostate cancer patients from the early- to the late-stage of this disease, has projected peak sales potential of more than three billion euros. Its market share in the US has already expanded to over 30 percent in non-metastatic castration-resistant ...
ByBayer AG
Prostate cancer is the most common type of cancer in men. Every year this diagnosis is made about 900 thousand times, in developed countries the disease affects up to 14% of the entire male population with oncology due to longer life expectancy. We spoke with adult prostate cancer survivors. ...
The compound is also being investigated in further studies across various stages of prostate cancer. “Darolutamide plus ADT and docetaxel has shown significant benefit in overall survival and a favorable safety profile for patients with metastatic hormone-sensitive prostate cancer,” said Matthew ...
ByBayer AG
Extended survival and tumor shrinkage in advanced breast cancer patients who matched the immunotherapy HLA types, lead to the development of BriaCell’s prostate cancer program based on the patient’s HLA type. ...
Health Technology Wales (HTW) has published guidance recommending the routine adoption of Extreme Hypofractionated Radiotherapy (EHFRT) for the treatment of localised prostate. In the UK, prostate cancer is the most common cancer in men and in Wales, more than 2,500 men each year are diagnosed with prostate ...
About Metastatic Hormone-Sensitive Prostate Cancer Prostate cancer is the second most commonly diagnosed malignancy in men worldwide. In 2020, an estimated 1.4 million men were diagnosed with prostate cancer, and about 375,000 died from the disease worldwide.1 At the time of diagnosis, most men ...
ByBayer AG
OnkosXcel, a Company subsidiary, to utilize proprietary AI-powered platform to progress therapies to address difficult-to-treat cancers with high unmet need New structure to unlock growth opportunities and maximize value of neuroscience and immuno-oncology franchises Lead pipeline asset, BXCL701, has shown clinical proof-of-concept in aggressive forms of ...
NOTE: Axumin® (fluciclovine F 18) injection is FDA-approved for PET imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment. ...
Investigators from the University of Pittsburgh School of Medicine have published a clinical study that demonstrates excellent outcomes for localized intermediate-risk prostate cancer patients treated with Isoray’s Cesium-131 brachytherapy, commercially known as Cesium Blu. ...
“We expect that IsoPSA, our novel blood-based prostate cancer test, may fundamentally shift the diagnostic paradigm of prostate cancer, and improve patient care and ...
“These results are an important step forward for the treatment of patients with metastatic hormone-sensitive prostate cancer.” “With the ARASENS results in mHSPC adding to the existing Phase III ARAMIS data in non-metastatic castration-resistant prostate cancer (nmCRPC), darolutamide has now ...
ByBayer AG
Raise in peak sales expectations follows presentation of positive Phase III trial ARASENS with darolutamide (Nubeqa) in metastatic hormone-sensitive prostate cancer at 2022 ASCO GU Cancers Symposium and publication in The New England Journal of Medicine on February 17, 2022 Broad development program underway with three additional ongoing or ...
ByBayer AG
“This is the ideal venue to present the new data evaluating SOZO to assess changes in bone in cancer patients during and after treatment. We continue to stay focused on lymphedema in the near term while exploring new ways to use SOZO in caring for cancer patients as part of our long-term oncology growth strategy.” ...